Misiu, what do you think about this drug that may
Post# of 145467
Coincidentally, it's a company that has emerged from being buried by Shkreli, he was once the company's CEO. Now they seem to have assembled a strong management team.
The drug is another monoclonal antibody, called Lenzilumab, that is only in Phase 1/2 but claims to significantly lower the toxicity of CAR-T therapy by neutralizing GM-CSF. The ultimate hope is that it becomes indispensable in CAR-T treatment. Here is the info on their site:
https://9e234b13-0cc4-4c74-b924-d7874342289e....bf0215.pdf
I'm definitely keeping it on my radar as a possible future investment.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)